Neurofit Signs Joint Research Agreement on Brain Imaging Analysis with Nanyang Technological University Dementia Research Center in Singapore

[Asia Economy Reporter Jang Hyowon] Neurophyt, a specialized company in brain disease imaging artificial intelligence (AI) solutions, announced on the 10th that it has signed a joint research agreement on brain imaging analysis with the Dementia Research Centre under the Lee Kong Chian School of Medicine at Nanyang Technological University (NTU), Singapore.

Through this agreement, Neurophyt and NTU's Dementia Research Centre plan to analyze brain imaging data held by the Dementia Research Centre using Neurophyt's flagship brain neurodegeneration imaging analysis software, 'Neurophet AQUA.' Based on the analysis results, they will conduct joint clinical research in the future and publish research papers in global conferences or academic journals.

NTU is one of Singapore's two major national universities and is a prestigious institution demonstrating global influence in engineering and science technology research fields. The NTU Dementia Research Centre was established by Professor Nagaendran Kandiah, known as one of the leading authorities in dementia in Singapore, conducting multifaceted research for early diagnosis, prevention, and treatment of dementia and Alzheimer's disease.

Neurologist Professor Nagaendran Kandiah is conducting extensive research on dementia diseases such as mild cognitive impairment, Alzheimer's disease, Parkinson's disease dementia, and frontotemporal dementia. After long discussions on research collaboration with Neurophyt, they have now officially started joint research through this agreement.

Neurophet AQUA is a brain imaging analysis medical device software that analyzes brain MRI (magnetic resonance imaging) using AI technology to assess brain atrophy and white matter degeneration observed in neurodegenerative diseases such as Alzheimer's disease and vascular dementia. The AI engine can analyze brain structures regardless of race, age, or gender, and can segment and analyze brain images within 5 minutes.

Neurophet AQUA, which received Class 2 medical device certification from the Korean Ministry of Food and Drug Safety in 2020, obtained European CE certification last year and medical device certification from Japan's Ministry of Health, Labour and Welfare (MHLW) in March. Currently, Neurophyt is in the process of obtaining certification from Singapore's Health Sciences Authority (HSA) for Neurophet AQUA.

Bin Jungil, CEO of Neurophyt, said, "Through this agreement, we can officially start global research and clinical trials with the Dementia Research Centre at NTU, a prestigious Asian university renowned in science and technology research." He added, "This agreement is not just a simple research collaboration but will serve as a foundation for Neurophyt's entry into the Southeast Asian market."

He continued, "We will actively collaborate with Professor Nagaendran Kandiah, one of the world's leading authorities in dementia, to achieve meaningful research outcomes in the analysis and treatment of dementia diseases," emphasizing his commitment.

This content was produced with the assistance of AI translation services.